EXPIRED
July 2, 2021
PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
PA-18-935 - Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)
NOT-OD-20-128 - Notice of Requirement for Electronic Submission of all Administrative Supplements
NOT-OD-20-118 - Guide Notice of Information Highlighting Harmonization and Data Sharing Expectations for Supplement and Revision Projects Addressing Social, Behavioral, Economic and Health Impacts of the COVID-19 Public Health Emergency
NOT-OD-20-018 - UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is issuing this Notice of Special Interest (NOSI) in response to the need for research on how infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent for Coronavirus Disease 2019 (COVID-19), may affect individuals with HIV and associated comorbidities, coinfections, and complications (CCCs). NICHD supports biomedical research to understand the effects of infection with HIV and SARS-CoV-2 among populations central to the NICHD mission, including pregnant, postpartum, and lactating women, infants, children, adolescents and young adults, people with intellectual and developmental disabilities, and individuals with physical disabilities or mobility impairments. This funding opportunity announcement encourages studies to examine the effect of the COVID -19 pandemic and infection with SARS-CoV-2 on social, behavioral and health outcomes in people with HIV (PLWH). Studies are expected to align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR) in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
Background:
The current COVID-19 pandemic continues to have a profound public health consequence in the United States (US) and globally. SARS-CoV-2 and HIV are considered syndemic since they occur together and disproportionally affect similar vulnerable populations. HIV co-morbidities and/or co-infections are considered risk factors for severe COVID-19 disease and the disruption in services for care and treatment of people living with HIV (PLWH) may have implications on susceptibility to COVID-19 and subsequent transmission of SARS-CoV-2 variants by PLWH with unsuppressed viral loads. Further, among at-risk communities, the social, medical and community structures that underpin control of HIV transmission remain hindered by the COVID pandemic, especially in the US among concentrated hot spots and generally across low and middle income countries (LMIC). In addition to horizontal transmission, the risk of mother-to-child transmission (MTCT) of HIV among those affected by SARS-CoV-2, whether by maternal co-infection or by pandemic effect on HIV services, remains poorly understood.
Because service disruptions have far reaching effects on health outcomes, including MTCT, of PLWH and those at risk, studies to expand our understanding of the consequences of COVID-19 disease in these populations are needed. Studies that explore the social and behavioral health determinants of PLWH and those at risk, before and during the pandemic and after SARS-CoV-2 vaccine implementation, including attitudes concerning COVID 19 and vaccination should be considered. In addition, the pathogenic mechanisms associated with SARS-CoV-2 transmission, and infection, including risk factors for severe COVID-19 and the long-term consequences such as post-acute sequalae (PASC) in vulnerable populations of infants, children, adolescents and young adults, and pregnant women at risk for and those living with HIV need further study. Finally, the biologic interactions of HIV, its associated comorbidities, coinfections, and complications, including TB, CMV, obesity, Type I, II and gestational diabetes and SARS-CoV-2 infection need to be explored. This NOSI is intended to cover both COVID-related and COVID-affected HIV research.
Research Objectives:
NICHD encourages the submission of applications for Competitive revisions and Administrative Supplements to active HIV grants to address the following research areas of interest within the HIV mission of NICHD:
Application and Submission Information
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalents:
When developing applications in response to this NOSI, all instructions in the SF424 (R&R) Application Guide, PA-20-272, and PA-18-935 must be followed, with the following additions:
Data Harmonization
Researchers addressing COVID-19 questions, whether population-based or for clinical research, are advised to consider the COVID-19 specific survey item repositories and select existing survey items or protocol modules. Existing COVID-19 survey items are publicly available through two NIH-supported platforms: the NIH Public Health Emergency and Disaster Research Response (DR2) [https://dr2.nlm.nih.gov/] and the PhenX Toolkit [https://www.phenxtoolkit.org/index.php]. Investigators are encouraged to use these data resources.
Review Process
NICHD staff will conduct administrative reviews of applications that will then be prioritized. Applications for competitive revisions will be evaluated for scientific and technical merit by an appropriate review panel convened by CSR.
Criteria:
All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:
Applicants are strongly encouraged to discuss any application in response to this NOSI with the scientific program staff listed below.
Denise Russo, PhD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-640-6328
E-mail: [email protected]